快而精醫藥 QGEN 深 滬
等待開盤 01-29 09:30:00 美东时间
53.995
-0.225
-0.41%
華盛通- 最 高54.00
- 今 開53.48
- 成交量 257.60万股
- 最 低 53.175
- 昨 收 54.22
- 總市值 111.77亿
- 52周最高 57.815
- 市盈率 靜 134.05
- 換手率 1.24%
- 52周最低 36.9369
- 委 比 44.55%
- 總股本 2.07亿
- 歷史最高 60.3887
- 量 比 0.58
- 振 幅 1.52%
- 歷史最低 7.7822
- 每 手 1
- 風險率 3.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
Deutsche Bank Downgrades Qiagen to Hold, Raises Price Target to $54
Deutsche Bank analyst Jan Koch downgrades Qiagen (NYSE:QGEN) from Buy to Hold and raises the price target from $52 to $54.
01-22 18:12
Qiagen Explores Possible Sale After New Buyer Talks: Report
Qiagen is reviewing strategic options, including a potential sale, after renewed takeover interest from several buyers.
01-21 21:11
'Qiagen Is Said to Consider Strategic Options Amid Fresh Interest' - Bloomberg
https://www.bloomberg.com/news/articles/2026-01-20/qiagen-is-said-to-consider-strategic-options-amid-fresh-interest
01-21 00:46
QIAGEN Shares To Begin Trading On January 8, 2026, Post-Reverse Stock Split On NYSE And Frankfurt Exchange
The last day of trading of the pre-split shares on the New York Stock Exchange and the Frankfurt Stock Exchange is planned to be Wednesday, January 7, 2026.Beginning on Thursday, January 8, 2026, the consolidated QIAGEN
2025-12-19 00:31
QIAGEN To Return $500M To Shareholders Through Synthetic Share Repurchase And Reverse Stock Split; Every 20 Issued QIAGEN Shares Will Be Consolidated Into 19 QIAGEN Shares, Leading To A Reduction Of ~10.9M Shares From The Level Of 217.7M Shares
Return of approximately $500 million – maximum approved by shareholders – set to be completed on January 7, 2026Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment
2025-12-19 00:30
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Citigroup Downgrades Qiagen to Neutral, Lowers Price Target to $50
Citigroup analyst Patrick Donnelly downgrades Qiagen (NYSE:QGEN) from Buy to Neutral and lowers the price target from $55 to $50.
2025-12-11 22:11
